2024
Detection, Patterns, and Outcomes of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Shah R, Wilkins S, Safranek C, Shah H, Brophy C, Mehra S. Detection, Patterns, and Outcomes of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head & Neck Surgery 2024, 150: 1105-1112. PMID: 39418066, PMCID: PMC11581730, DOI: 10.1001/jamaoto.2024.3237.Peer-Reviewed Original ResearchHPV-positive oropharyngeal squamous cell carcinomaOropharyngeal squamous cell carcinomaSquamous cell carcinomaDistant metastasisDisease recurrenceCell carcinomaRecurrence detectionHuman papillomavirus (HPV)-positive oropharyngeal squamous cell carcinomaCohort studyMethod of recurrence detectionSurveillance strategiesSurveillance imaging strategiesLocation of recurrencePatterns of recurrenceFollow-up timeElectronic medical record reviewOptimal surveillance strategyPercentage of patientsRetrospective cohort studyIncidence of DMTertiary care hospitalDiagnosis to deathMedical record reviewRecurrence cohortRegional recurrenceReview of the cost-effectiveness of surveillance for hereditary pancreatic cancer
Wang L, Levinson R, Mezzacappa C, Katona B. Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer. Familial Cancer 2024, 23: 351-360. PMID: 38795221, PMCID: PMC11255025, DOI: 10.1007/s10689-024-00392-1.Peer-Reviewed Original ResearchHigh-risk individualsHereditary pancreatic cancerSusceptibility to pancreatic cancerPancreatic cancer riskFamily history of PCSurveillance strategiesPancreatic cancerCost-effectiveness of surveillanceHistory of PCCost-effectiveness studiesCost-effectiveCancer riskCost-effectiveness analysisPancreatic surveillanceHigh-risk groupOptimal surveillance strategyFamily historyNew-onset diabetesRisk individualsSporadic PCHealth benefitsPotential health benefitsPC diagnosisSub-groupsSurveillance
2023
Coronavirus sampling and surveillance in bats from 1996–2019: a systematic review and meta-analysis
Cohen L, Fagre A, Chen B, Carlson C, Becker D. Coronavirus sampling and surveillance in bats from 1996–2019: a systematic review and meta-analysis. Nature Microbiology 2023, 8: 1176-1186. PMID: 37231088, PMCID: PMC10234814, DOI: 10.1038/s41564-023-01375-1.Peer-Reviewed Original ResearchSurveillance of Pancreatic Cystic Neoplasms
Chhoda A, Schmidt J, Farrell J. Surveillance of Pancreatic Cystic Neoplasms. Gastrointestinal Endoscopy Clinics Of North America 2023, 33: 613-640. PMID: 37245939, DOI: 10.1016/j.giec.2023.03.010.Peer-Reviewed Original ResearchConceptsPancreatic cystic neoplasmsAdvanced neoplasiaCystic neoplasmsIntraductal papillary mucinous neoplasmClinical surveillance guidelinesHigh-risk morphologyConsensus clinical guidelinesPapillary mucinous neoplasmAccurate preoperative diagnosisCross-sectional imagingSurgical resectionSurgical indicationsPreoperative diagnosisSurveillance guidelinesSurveillance intervalsMucinous neoplasmsMalignant potentialClinical evaluationClinical guidelinesPancreatic cystsClinical challengeSurveillance strategiesNeoplasmsNeoplasiaCurrent concepts
2021
Machine Learning–Based Surveillance Strategy after Complete Ablation of Initially Recurrent Hepatocellular Carcinoma: Worth the Risk?
Nam D, Chapiro J. Machine Learning–Based Surveillance Strategy after Complete Ablation of Initially Recurrent Hepatocellular Carcinoma: Worth the Risk? Journal Of Vascular And Interventional Radiology 2021, 32: 1558-1559. PMID: 34717834, DOI: 10.1016/j.jvir.2021.08.014.Peer-Reviewed Original Research
2020
Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
Barnes JI, Lin JK, Gupta D, Owens DK, Goldhaber-Fiebert JD, Kunz PL. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. Journal Of The National Comprehensive Cancer Network 2020, 18: 1200-1209. PMID: 32886901, DOI: 10.6004/jnccn.2020.7563.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioMetastatic enteropancreatic neuroendocrine tumorsEnteropancreatic neuroendocrine tumorsNeuroendocrine tumorsInitial therapyActive surveillanceNCCN Clinical Practice GuidelinesProlonged progression-free survivalProgression-free survivalClinical practice guidelinesActive surveillance strategyLifetime time horizonCost-effectiveness ratioHealthcare sector perspectiveProbabilistic sensitivity analysesCLARINET trialPostprogression treatmentPlacebo armAdrenal tumorsTumor trialsTreatment optionsPractice guidelinesLanreotideSurveillance strategiesQALYAdaptive guidelines for the treatment of gonorrhea to increase the effective life span of antibiotics among men who have sex with men in the United States: A mathematical modeling study
Yaesoubi R, Cohen T, Hsu K, Gift TL, Chesson H, Salomon JA, Grad YH. Adaptive guidelines for the treatment of gonorrhea to increase the effective life span of antibiotics among men who have sex with men in the United States: A mathematical modeling study. PLOS Medicine 2020, 17: e1003077. PMID: 32243443, PMCID: PMC7122693, DOI: 10.1371/journal.pmed.1003077.Peer-Reviewed Original ResearchConceptsFirst-line antibioticsPrevalence of resistanceMSM populationGonorrhea casesPrevalence of gonorrheaTreatment of gonorrheaTransmission of gonorrheaIncidence of gonorrhoeaGonococcal antimicrobial resistanceProportion of casesAlternative surveillance strategiesBurden of gonorrheaEffective surveillance systemTreatment guidelinesGonorrhea treatmentGonorrhoea transmissionClinical effectivenessOverall burdenSurveillance estimatesLife spanGonorrheaDrug susceptibilitySurveillance findingsSurveillance strategiesSurveillance program
2019
Return of the founder Chikungunya virus to its place of introduction into Brazil is revealed by genomic characterization of exanthematic disease cases
Maia Z, Pereira F, do Carmo Said R, Fonseca V, Gräf T, de Bruycker Nogueira F, Nardy V, Xavier J, Maia M, Abreu A, de Albuquerque C, Oliveira W, Croda J, de Filippis A, Cunha R, Lourenço J, de Oliveira T, Faria N, Alcantara L, Giovanetti M. Return of the founder Chikungunya virus to its place of introduction into Brazil is revealed by genomic characterization of exanthematic disease cases. Emerging Microbes & Infections 2019, 9: 53-57. PMID: 31880218, PMCID: PMC6968431, DOI: 10.1080/22221751.2019.1701954.Peer-Reviewed Original ResearchConceptsNumber of patientsGenomic surveillance strategiesFebrile illnessArboviral infectionsEpidemic seasonChikungunya virusWhole-genome sequencingDisease casesSurveillance strategiesGenetic diversityEpidemiological analysisMolecular clockCHIKV ECSA genotypeTransmission potentialGenome sequencingArboviral transmissionGenomic characterizationCHIKVLocal persistenceLung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Journal Of Clinical Oncology 2019, 38: 753-766. PMID: 31829901, DOI: 10.1200/jco.19.02748.Peer-Reviewed Original ResearchConceptsCurative-intent therapyLung cancerStage IFluorodeoxyglucose positron emission tomography/Evidence-based guideline recommendationsNew primary lung cancerRetrospective comparative observational studySurveillance strategiesSmall cell lung cancerBrain magnetic resonance imagingLiterature searchPositron emission tomography/Lung cancer surveillanceCurative-intent treatmentPrimary lung cancerRecurrence-free survivalCell lung cancerDetection of recurrenceComparative observational studyEmission tomography/Optimal imaging modalityEvidence-based recommendationsOutcomes of interestQuality of lifeMagnetic resonance imagingAdaptive Imaging Versus Periodic Surveillance for Intrafraction Motion Management During Prostate Cancer Radiotherapy
Ma X, Yan H, Nath R, Chen Z, Li H, Liu W. Adaptive Imaging Versus Periodic Surveillance for Intrafraction Motion Management During Prostate Cancer Radiotherapy. Technology In Cancer Research & Treatment 2019, 18: 1533033819844489. PMID: 31177934, PMCID: PMC6558533, DOI: 10.1177/1533033819844489.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiation therapyRadiation therapyCouch shiftsAutomatic motion compensationAdaptive imagingAutomatic correctionCurrent clinical situationProstate cancer radiotherapyImaging surveillanceMotion compensationPeriodic imaging surveillanceProstate cancerPeriodic surveillanceClinical situationsSurveillance strategiesBenefits of adaptivePeriodic imagingArc therapyMean percentageTherapyIntrafraction motion managementCancer radiotherapyRadiation therapy simulationTherapy simulationBeam delivery
2016
Conditional Survival as a Patient Centered Metric for Patients with Appendiceal Adenocarcinoma
Sekigami Y, Rajeev R, Johnston F, Clark Gamblin T, Turaga K. Conditional Survival as a Patient Centered Metric for Patients with Appendiceal Adenocarcinoma. Annals Of Surgical Oncology 2016, 23: 2295-2301. PMID: 26856719, DOI: 10.1245/s10434-016-5105-7.Peer-Reviewed Original ResearchConceptsAppendiceal adenocarcinomaMetastatic diseaseOverall survivalFive-year overall survivalConditional survivalCumulative probability of survivalActuarial life table analysisKaplan-Meier curvesSignet ring cellsLife table analysisExtended surgeryMucinous adenocarcinomaMedian ageAdenocarcinoma patientsPatients' better understandingFollow-upAdenocarcinomaProbability of survivalRing cellsBurden of diseasePatientsSurveillance strategiesNature of therapyNOSSurvival
2015
Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission
Huntington SF, Svoboda J, Doshi JA. Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal Of Clinical Oncology 2015, 33: 1467-1474. PMID: 25823735, DOI: 10.1200/jco.2014.58.5729.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisDecision Support TechniquesFluorodeoxyglucose F18Health Care CostsHumansImmunotherapyLymphoma, Large B-Cell, DiffuseMarkov ChainsMiddle AgedModels, EconomicMultimodal ImagingPositron-Emission TomographyPredictive Value of TestsQuality-Adjusted Life YearsRadiopharmaceuticalsRemission InductionTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsDiffuse large B-cell lymphomaQuality-adjusted life yearsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaComputed tomographySurveillance imagingCost-effectiveness analysisSurveillance strategiesFirst remissionFluorodeoxyglucose positron emission tomography-computed tomographyPositron emission tomography-computed tomographyEmission tomography-computed tomographyPET/CT scansPET/Computed TomographyFirst-line immunochemotherapyRoutine surveillance imagingMinimal survival benefitDecision-analytic Markov modelLittle clinical benefitRoutine computed tomographyImproved clinical outcomesTomography-computed tomographyCost-effectiveness ratioProbabilistic sensitivity analyses
2014
Active Surveillance for Carbapenem-Resistant Enterobacteriaceae Using Stool Specimens Submitted for Testing for Clostridium difficile
Banach DB, Francois J, Blash S, Patel G, Jenkins SG, LaBombardi V, Kreiswirth BN, Srinivasan A, Calfee DP. Active Surveillance for Carbapenem-Resistant Enterobacteriaceae Using Stool Specimens Submitted for Testing for Clostridium difficile. Infection Control And Hospital Epidemiology 2014, 35: 82-84. PMID: 24334803, PMCID: PMC3984911, DOI: 10.1086/674391.Peer-Reviewed Original Research
2013
Risk of Cancer in Cases of Suspected Lynch Syndrome Without Germline Mutation
Rodríguez–Soler M, Pérez–Carbonell L, Guarinos C, Zapater P, Castillejo A, Barberá VM, Juárez M, Bessa X, Xicola RM, Clofent J, Bujanda L, Balaguer F, Reñé J, de–Castro L, Marín–Gabriel J, Lanas A, Cubiella J, Nicolás–Pérez D, Brea–Fernández A, Castellví–Bel S, Alenda C, Ruiz–Ponte C, Carracedo A, Castells A, Andreu M, Llor X, Soto JL, Payá A, Jover R. Risk of Cancer in Cases of Suspected Lynch Syndrome Without Germline Mutation. Gastroenterology 2013, 144: 926-932.e1. PMID: 23354017, DOI: 10.1053/j.gastro.2013.01.044.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overColorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairDNA RepairDNA, NeoplasmFemaleGerm-Line MutationHumansImmunohistochemistryIncidenceMaleMicrosatellite InstabilityMiddle AgedMutL Protein Homolog 1Nuclear ProteinsPopulation SurveillanceRisk FactorsSpainConceptsLynch-like syndromeSex-adjusted standardized incidence ratiosFamilies of patientsRisk of cancerIncidence of CRCLynch syndromePathogenic germline mutationsMicrosatellite instabilityGermline mutationsSporadic CRCStandardized incidence ratiosLoss of PMS2Population-based cohortMLH1 promoter hypermethylationLoss of MLH1Loss of MSH2Clinical characteristicsConsecutive patientsIncidence ratiosMSH6 expressionImmunohistochemical analysisPatientsMLH1 promoterSyndromeSurveillance strategies
2012
Susceptibility genetic variants associated with early-onset colorectal cancer
Giráldez MD, López-Dóriga A, Bujanda L, Abulí A, Bessa X, Fernández-Rozadilla C, Muñoz J, Cuatrecasas M, Jover R, Xicola RM, Llor X, Piqué JM, Carracedo A, Ruiz-Ponte C, Cosme A, Enríquez-Navascués JM, Moreno V, Andreu M, Castells A, Balaguer F, Castellví-Bel S, Association T. Susceptibility genetic variants associated with early-onset colorectal cancer. Carcinogenesis 2012, 33: 613-619. PMID: 22235025, DOI: 10.1093/carcin/bgs009.Peer-Reviewed Original ResearchConceptsEarly-onset colorectal cancerColorectal cancerFamily historyCRC susceptibility variantsRisk allelesCRC family historyLynch syndrome spectrumHigh-risk groupEarly-onset casesRisk allele carriersCRC burdenGenotype-phenotype correlationCRC groupEntire cohortCommon cancerPathological characteristicsAllele carriersHereditary predispositionSusceptibility variantsGenetic susceptibility lociSurveillance strategiesHereditary formsSyndrome spectrumPatientsCancer
2010
Susceptibility Genetic Variants Associated With Colorectal Cancer Risk Correlate With Cancer Phenotype
Abulí A, Bessa X, González JR, Ruiz–Ponte C, Cáceres A, Muñoz J, Gonzalo V, Balaguer F, Fernández–Rozadilla C, González D, de Castro L, Clofent J, Bujanda L, Cubiella J, Reñé J, Morillas JD, Lanas Á, Rigau J, García A, Latorre M, Saló J, Bañares F, Argüello L, Peña E, Vilella À, Riestra S, Carreño R, Paya A, Alenda C, Xicola RM, Doyle BJ, Jover R, Llor X, Carracedo A, Castells A, Castellví–Bel S, Andreu M, Association G. Susceptibility Genetic Variants Associated With Colorectal Cancer Risk Correlate With Cancer Phenotype. Gastroenterology 2010, 139: 788-796.e6. PMID: 20638935, DOI: 10.1053/j.gastro.2010.05.072.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCell DifferentiationChromosomes, Human, Pair 16Chromosomes, Human, Pair 8Colorectal NeoplasmsFemaleGene Expression Regulation, NeoplasticGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseHumansLogistic ModelsMaleMiddle AgedNeoplasm StagingOdds RatioPedigreePhenotypePolymorphism, Single NucleotideProspective StudiesReproducibility of ResultsRisk AssessmentRisk FactorsSpainConceptsCRC phenotypeColorectal cancer riskPopulation-based cohortAdvanced stage tumorsCancer phenotypeGenetic variantsCRC managementSpanish cohortColorectal adenomasCancer riskFamilial historyG allelePatientsC alleleGenetic Variants AssociatedPrevention programsSurveillance strategiesAbstractTextLogistic regressionRisk correlatesCRCAIMSReplication setCohortVariants Associated
2008
Are Survey-Based Estimates of the Burden of Drug Resistant TB Too Low? Insight from a Simulation Study
Cohen T, Colijn C, Finklea B, Wright A, Zignol M, Pym A, Murray M. Are Survey-Based Estimates of the Burden of Drug Resistant TB Too Low? Insight from a Simulation Study. PLOS ONE 2008, 3: e2363. PMID: 18523659, PMCID: PMC2408555, DOI: 10.1371/journal.pone.0002363.Peer-Reviewed Original ResearchConceptsResistant tuberculosisIncident casesTotal burdenDrug-resistant TBDrug-resistant tuberculosisSecond-line antibioticsDrug treatment regimensDrug sensitivity testingDrug-resistant strainsBurden of resistanceEmergence of tuberculosisResistant TBTreatment regimensPrevalent casesWorldwide burdenIntroduction of interventionsRoutine surveillanceSurveillance strategiesDrug resistanceTuberculosisLaboratory capacityMycobacterium tuberculosisSensitivity testingTuberculosis modelBurdenUnexplained Deaths in Connecticut, 2002–2003:Failure to Consider Category A Bioterrorism Agents in Differential Diagnoses
Palumbo JP, Meek JI, Fazio DM, Turner SB, Hadler JL, Sofair AN. Unexplained Deaths in Connecticut, 2002–2003:Failure to Consider Category A Bioterrorism Agents in Differential Diagnoses. Disaster Medicine And Public Health Preparedness 2008, 2: 87-94. PMID: 18525371, DOI: 10.1097/dmp.0b013e318161315b.Peer-Reviewed Original ResearchConceptsInfectious deathUnexplained deathDifferential diagnosisConnecticut death certificatesInitial casesEmergency department cliniciansBioterrorism agentsCategory A Bioterrorism AgentsClinical presentationClinician educationDeath certificatesDiagnostic testingSurveillance strategiesConnecticut physiciansFirst lineDeathChart informationDiagnosisTularemiaBioterrorism attackBioterrorist attackSmallpoxAnthraxBotulismSerology
2007
Follow-up care of patients with breast cancer
Tolaney SM, Winer EP. Follow-up care of patients with breast cancer. The Breast 2007, 16: 45-50. PMID: 17697780, DOI: 10.1016/j.breast.2007.07.005.Peer-Reviewed Original ResearchConceptsBreast cancerEarly detectionNew primary cancerInvasive breast cancerBreast cancer survivorsLong-term complicationsRoutine imaging studiesCare of patientsLocoregional recurrenceDistant metastasisPrimary cancerCancer survivorsDuctal carcinomaNew casesSurveillance strategiesImaging studiesCancerFurther studiesRecurrenceCareWomenComplicationsPatientsCarcinomaMetastasis
2005
Intermittent Cardiac Troponin-I Screening is an Effective Means of Surveillance for a Perioperative Myocardial Infarction
Martinez EA, Nass CM, Jermyn RM, Rosenbaum SH, Akhtar S, Chan DW, Malkus H, Weiss JL, Fleisher LA. Intermittent Cardiac Troponin-I Screening is an Effective Means of Surveillance for a Perioperative Myocardial Infarction. Journal Of Cardiothoracic And Vascular Anesthesia 2005, 19: 577-582. PMID: 16202889, DOI: 10.1053/j.jvca.2005.07.002.Peer-Reviewed Original ResearchConceptsHigh diagnostic yieldPositive predictive valueDiagnosis of MIPostoperative day 1Myocardial infarctionDiagnostic yieldCardiac troponinNoncardiac surgeryCardiac injuryCreatine kinaseDay 1Surveillance strategiesIncidence of MIPerioperative cardiac injuryHigh-risk patientsPerioperative myocardial infarctionSubset of patientsIU/LGreater positive predictive valueTotal creatine kinaseCK-MB massCardiac protein markersPerioperative incidencePerioperative surveillanceCohort study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply